Table 3.
Univariate and multivariate analyses of PFS in patients
| Characteristic | Before PSM | After PSM | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Univariate analysis | Multivariate analysis | Univariate analysis | Multivariate analysis | ||||||||||
| HR | 95%CI | P | HR | 95%CI | P | HR | 95%CI | P | HR | 95% CI | P | ||
| Age (years) | ≤60/> 60 | 1.178 | 0.674–2.058 | 0.566 | NI | 0.956 | 0.547–1.671 | 0.874 | NI | ||||
| Gender | Female / Male | 1.587 | 0.905–2.783 | 0.107 | NI | 2.284 | 1.269–4.112 | 0.006 | 1.798 | 0.966–3.330 | 0.064 | ||
| Tumor size (cm) | ≤2/2~4/>4 | 0.787 | 0.490–1.265 | 0.324 | NI | 0.970 | 0.596–1.579 | 0.903 | NI | ||||
| Tumor grade | Well / Moderate / Poor | 1.135 | 0.735–1.753 | 0.568 | NI | 1.333 | 0.855–2.079 | 0.205 | NI | ||||
| LN metastasis | Absent / Present | 0.900 | 0.501–1.614 | 0.723 | NI | 1.078 | 0.600–1.938 | 0.801 | NI | ||||
| Tumor site | Head / Body / Tail | 0.935 | 0.621–1.407 | 0.748 | NI | 0.995 | 0.650–1.525 | 0.983 | NI | ||||
| WBC (*109) | ≤10/>10 | 1.149 | 0.486–2.718 | 0.751 | NI | 1.019 | 0.431–2.411 | 0.965 | NI | ||||
| HGB (g/L) | ≤120/>120 | 0.685 | 0.308–1.527 | 0.355 | NI | 0.477 | 0.211–1.076 | 0.075 | NI | ||||
| PLT (*109) | ≤300/>300 | 0.613 | 0.261–1.438 | 0.261 | NI | 0.676 | 0.287–1.592 | 0.370 | NI | ||||
| ALT (U/L) | ≤40/>40 | 0.729 | 0.373–1.426 | 0.356 | NI | 0.737 | 0.375–1.447 | 0.375 | NI | ||||
| AST (U/L) | ≤40/>40 | 0.662 | 0.309–1.417 | 0.288 | NI | 0.691 | 0.320–1.490 | 0.345 | NI | ||||
| ALP (U/L) | ≤100/>100 | 0.823 | 0.459–1.476 | 0.514 | NI | 0.790 | 0.439–1.423 | 0.433 | NI | ||||
| GGT (U/L) | ≤45/>45 | 0.693 | 0.390–1.230 | 0.210 | NI | 0.741 | 0.414–1.327 | 0.313 | NI | ||||
| ALB (g/L) | ≤40/>40 | 0.602 | 0.253–1.429 | 0.250 | NI | 0.666 | 0.281–1.582 | 0.357 | NI | ||||
| TBIL (umol/L) | ≤20.5/>20.5 | 0.691 | 0.336–1.423 | 0.316 | NI | 0.721 | 0.350–1.487 | 0.376 | NI | ||||
| IBIL (umol/L) | ≤15/>15 | 0.884 | 0.317–2.461 | 0.813 | NI | 0.769 | 0.276–2.144 | 0.616 | NI | ||||
| CRP (ng/L) | ≤3/>3 | 1.840 | 1.030–3.286 | 0.040 | 1.586 | 0.877–2.866 | 0.127 | 1.763 | 0.970–3.202 | 0.063 | NI | ||
| CEA (ng/mL) | ≤5/>5 | 1.466 | 0.835–2.572 | 0.183 | NI | 1.464 | 0.829–2.586 | 0.189 | NI | ||||
| CA19–9 (U/ml) | ≤35/>35 | 2.078 | 1.009–4.279 | 0.047 | 1.908 | 0.917–3.968 | 0.084 | 2.530 | 1.179–5.429 | 0.017 | 2.032 | 0.904–4.569 | 0.086 |
| Chemotherapy | With IRE/ With radiotherapy | 0.557 | 0.310–1.000 | 0.050 | 0.582 | 0.322–0.950 | 0.048 | 0.435 | 0.242–0.783 | 0.005 | 0.438 | 0.243–0.790 | 0.006 |
| Cheotherapy type | FOLFIRINOX/Gem | 0.965 | 0.733–1.271 | 0.803 | NI | 1.014 | 0.768–1.340 | 0.921 | NI | ||||
Abbreviations as in Table 1